Claims for Patent: 10,526,631

Summary for Patent: 10,526,631

Title:	Method of reducing serine for asparagine misincorporation
Abstract:	The present invention relates to a method of reducing serine for asparagine misincorporation in a protein produced by a culture of cells in a cell culture method, the method comprising the addition of asparagine and iron to the cell culture medium.
Inventor(s):	Solacroup; Thomas (Blonay, CH), Stettler; Matthieu (Vucherens, CH), Broly; Herve (Chatel-St-Denis, CH)
Assignee:	ARES TRADING S.A. (Aubonne, CH)
Application Number:	15/457,597
Patent Claims:	1. A cell culture method of reducing serine for asparagine misincorporation in a recombinant protein produced by a culture of cells in a cell culture medium, the method comprising supplementing the cell culture medium with asparagine and iron, wherein the concentration of iron in the cell culture medium is between 1.0 mg/L and 5.0 mg/L of culture medium at day 0 of the cell culture method, and wherein the misincorporation of serine for asparagine in the protein produced by the culture of cells is reduced. 2. A method of making a protein in a cell culture, comprising growing a host cell in a cell culture medium, wherein the concentration of iron in the cell culture medium is between 1.0 mg/L and 5.0 mg/L of culture medium at day 0 of the cell culture method, expressing the protein in the host cell, supplementing the cell culture medium with asparagine and iron, and purifying the protein from the cell culture. 3. The method of claim 2, wherein cell viability is maintained at a level of at least 80%. 4. The method of claim 3, wherein cell viability is maintained at the level of at least 80% for 18 days. 5. The method of claim 2, wherein the cell culture is a fed batch culture. 6. The method of claim 2, wherein the concentration of asparagine in the cell culture medium is between 8 mM and 15 mM at day 0. 7. The method of claim 2, wherein the concentration of asparagine in the cell culture medium is 12.5 mM or 18.5 mM at day 0. 8. The method of claim 2, wherein the concentration of iron in the cell culture medium is 3.0 mg/L of culture medium at day 0. 9. The method of claim 2, wherein the cell culture medium is supplemented with asparagine and/or iron at one or more days selected from the group consisting of day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10, day 11, day 12, day 13 and day 14. 10. The method of claim 2, wherein the cell culture medium is supplemented according to one or more methods selected from the group consisting of: (a) on day 3, the cell culture medium is supplemented with asparagine to a concentration of between 2.0 mM to 4.5 mM, in addition to any asparagine already present in the cell culture medium; (b) on day 5, the cell culture medium is supplemented with asparagine to a concentration of between 4.5 mM and 8.0 mM, in addition to any asparagine already present in the cell culture medium; and (c) on day 7 and/or day 10, the cell culture medium is supplemented with asparagine to a concentration of between 1.0 mM and 5.0 mM, in addition to any asparagine already present in the cell culture medium. 11. The method of claim 2, wherein the cell culture medium is supplemented according to one or more methods selected from the group consisting of: (a) on day 3, the cell culture medium is supplemented with asparagine to a concentration of 2.3 mM or 4.5 mM, in addition to any asparagine already present in the cell culture medium; (b) on day 5, the cell culture medium is supplemented with asparagine to a concentration of 4.8 mM or 6.9 mM, in addition to any asparagine already present in the cell culture medium; and (c) on day 7 and/or day 10, the cell culture medium is supplemented with asparagine to a concentration of 4.8 mM or 1.7 mM, in addition to any asparagine already present in the cell culture medium. 12. The method of claim 2, wherein on day 3, the cell culture medium is supplemented with iron to a concentration of between 0.5 mg/L and 2.0 mg/L, in addition to any iron already present in the cell culture medium. 13. The method of claim 2, wherein on day 3, the cell culture medium is supplemented with iron to a concentration of 0.9 mg/L or 1.5 mg/L, in addition to any iron already present in the cell culture medium. 14. The method of claim 2, wherein the cell culture medium is supplemented with iron to a concentration of between 1.0 mg/L and 4.0 mg/L on one or more days selected from the group consisting of day 5, day 7, and day 10, in addition to any iron already present in the cell culture medium. 15. The method of claim 2, wherein the cell culture medium is supplemented with iron to a concentration of 1.7 mg/L to 3.0 mg/L on one or more days selected from the group consisting of day 5, day 7, and day 10, in addition to any iron already present in the cell culture medium. 16. The method of claim 2, wherein the cell culture medium is serum-free and/or protein-free. 17. The method of claim 2, wherein the cell culture medium is supplemented with iron together with feed components in a feed medium. 18. The method of claim 2, wherein the host cell is a CHO cell. 19. The method of claim 2, wherein the cell culture method is carried out in a 3.5 L, 2800 L, 5000 L, or 15,000 L bioreactor. 20. The method of claim 2, further comprising supplementing the cell culture medium with manganese and/or glucose. 21. The method of claim 2, wherein the cell culture medium comprises an energy source, essential amino acids, vitamins, and/or trace elements. 22. The method of claim 2, wherein the protein is (a) tumor necrosis factor alpha (TNF.alpha.) binding protein; (b) an antibody; (c) adalimumab, infliximab, etanercept, or a biosimilar thereof; or (d) adalimumab or a biosimilar thereof having: (i) a light chain sequence having at least 90% identity with SEQ ID NO:1 and a heavy chain sequence having at least 90% identity with SEQ ID NO:2; (ii) a light chain sequence having at least 95% identity with SEQ ID NO:1 and a heavy chain sequence having at least 95% identity with SEQ ID NO:2; (iii) a light chain sequence of SEQ ID NO:1 and a heavy chain sequence of SEQ ID NO:2; (iv) a light chain sequence comprising SEQ ID NO: 3, SEQ ID NO: 5, and SEQ ID NO: 7; and a heavy chain sequence comprising SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 8; (v) a light chain sequence comprising SEQ ID NO: 3, SEQ ID NO: 5, and SEQ ID NO: 7, wherein Xaa in SEQ ID NO:3 is Threonine or Alanine, and a heavy chain sequence comprising SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 8; (vi) a light chain sequence comprising SEQ ID NO: 3, SEQ ID NO: 5, and SEQ ID NO: 7, and a heavy chain sequence comprising SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 8, wherein Xaa of SEQ ID NO: 4 is Tyrosine or Asparagine; or (vii) a light chain sequence comprising SEQ ID NO: 3, SEQ ID NO: 5, and SEQ ID NO: 7, wherein Xaa in SEQ ID NO:3 is Threonine or Alanine, and a heavy chain sequence comprising SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 8, wherein Xaa of SEQ ID NO: 4 is Tyrosine or Asparagine.

Details for Patent 10,526,631

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2040-01-24
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2040-01-24
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2040-01-24
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2040-01-24